Biomarin Pharmaceutical Inc (BMRN)
71.53
-0.46
(-0.64%)
USD |
NASDAQ |
Mar 25, 16:00
73.40
+1.87
(+2.61%)
After-Hours: 04:43
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 13.65B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -17.33% |
| Valuation | |
| PE Ratio | 32.51 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.973 |
| Price to Book Value | 2.412 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1052 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 53.26% |
Profile
Edit
| BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
| URL | https://www.biomarin.com |
| Investor Relations URL | https://investors.biomarin.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 24, 2025 (est.) |
| Last Earnings Release | Feb. 19, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
| URL | https://www.biomarin.com |
| Investor Relations URL | https://investors.biomarin.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 24, 2025 (est.) |
| Last Earnings Release | Feb. 19, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |